SINTX Technologies Files Multiple New U.S. and International Patent Applications

Rhea-AI Summary

SINTX Technologies announced multiple U.S. and international patent applications focusing on the development of technologies utilizing silicon nitride for antipathogenic applications. Key patents include methods for the rapid inactivation of SARS-CoV-2, antipathogenic face masks, and systems for applying silicon nitride coatings. These innovations aim to enhance medical devices and address viral diseases, including COVID-19. SINTX underscores its commitment to leveraging silicon nitride's properties in improving medical device outcomes. The company operates an FDA registered and certified manufacturing facility.

Positive

• Multiple patent applications for innovative antipathogenic technologies potentially enhance market position.
• Focus on developing products for COVID-19 in addition to other medical applications.

Negative

• Patent applications may not be granted or provide the expected protection.
• Risks associated with new product development may affect commercialization timelines and acceptance.

SALT LAKE CITY, May 04, 2021 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of silicon nitride ceramic for medical and non-medical applications, announced today multiple U.S. and international patent applications for development of new technologies utilizing the Company’s silicon nitride.

The following expand on several existing antipathogenic and coating-technology patent applications:

• Systems and Methods for Rapid Inactivation of SARS-CoV-2 by Silicon Nitride, Copper and Aluminum Nitride
• Antipathogenic Composites and Devices and Methods of Use Thereof
• Antipathogenic Face Mask
• Systems and Methods for Physical Vapor Deposition of Silicon Nitride Coatings Having Antimicrobial and Osteogenic Enhancements
• Methods of Silicon Nitride Laser Cladding
• Methods for Laser Coating of Silicon Nitride on a Metal Substrate

The patent applications largely relate to the development of antipathogenic and/or osteogenic composite systems, methods, devices, and surface coatings. The technologies can be applied in antipathogenic devices such as face masks and filters, or in medical devices such as orthopedic, wound care dressings, and dental implants. The patent applications are an important milestone in SINTX’s commitment to leverage the inherent antipathogenic and osteogenic properties of silicon nitride in powders and coatings to address viral diseases such as COVID-19 and to improve outcomes in medical device implantations.

About SINTX Technologies, Inc.
SINTX Technologies is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company presently manufactures silicon nitride powders and components in its FDA registered, ISO 13485:2016 certified, and ASD9100D certified manufacturing facility.

For more information on SINTX Technologies or its silicon nitride material platform, please visit www.sintx.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of risks and uncertainties. Risks and uncertainties that may cause such differences include, among other things: the patent applications may not be granted or may not afford the protection we are seeking; volatility in the price of SINTX’s common stock; the uncertainties inherent in new product development, including the cost and time required to commercialize such product(s); market acceptance of our products once commercialized; SINTX’s ability to raise funding and other competitive developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations, and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 22, 2021, and in SINTX’s other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.

Business Inquiries for SINTX:
SINTX Technologies
801.839.3502
IR@sintx.com

Media Inquiries for SINTX:
Amanda Barry
Associate Director, Content and PR
The Summit Group
abarry@summitslc.com

FAQ

What recent patent applications has SINTX submitted related to silicon nitride?

SINTX has submitted patent applications for technologies including the rapid inactivation of SARS-CoV-2 and antipathogenic face masks.

How does SINTX Technologies address COVID-19 through its new patent applications?

The new patent applications focus on using silicon nitride for devices aimed at inactivating SARS-CoV-2, contributing to the fight against COVID-19.

What is the significance of SINTX's recent patent applications?

These applications enhance SINTX's technological portfolio, potentially improving its market competitiveness in medical devices.

What risks are associated with SINTX's patent applications?

There is a risk that the patent applications may not be granted or may not provide the anticipated level of protection.

When was the press release about SINTX's new patent applications issued?

The press release was issued on May 4, 2021.